Bing-Neel syndrome successfully treated with venetoclax and zanubrutinib
Open Access
- 23 October 2026
- journal article
- research article
- Published by Wolters Kluwer Health in Medicine
- Vol. 105 (43) , e51158
Abstract
Rationale: Bing-Neel syndrome (BNS) is an uncommon neurological manifestation of Waldenström’s Macroglobulinemia (WM). The diagnosis of BNS is still challenging due to its low incidence and high heterogeneity. A definite diagnosis relies on histopathology and cerebrospinal fluid (CSF) analysis to identify lymphoplasmacytic lymphocyte infiltration of the central nervous system. MYD88 L265P mutation also serves as a valuable diagnostic tool. To date, there is no consensus on the standard management of BNS, and current evidence is largely limited to reports on the use of high-dose chemotherapy and BTK inhibitors. Herein, we present a case of BNS who achieved remission following treatment with venetoclax and zanubrutinib. Furthermore, venetoclax was detected in CSF. Patient concern: A 66-year-old female with WM presenting with a headache. Diagnoses: Bing-Neel syndrome. Interventions: The patient was diagnosed with BNS through CSF examination and treated with zanubrutinib plus venetoclax. Outcomes: The patient’s symptoms resolved, and abnormal B lymphocytes were not detected in CSF. Lesson: BNS is an uncommon manifestation of WM, with significant diagnostic challenges. In the absence of standard management for BNS, high-dose chemotherapy and BTK inhibitors are widely used as front-line approaches. BCL-2 inhibitors, which have shown notable CNS-penetrating capacity, hold considerable promise for the treatment of BNS and merit further exploration.Keywords
Funding Information
- Zhejiang Provincial Natural Science Foundation of China (ZCLQN25H1604)
- Medical and Health Research Program of Zhejiang (2025KY901)
This publication has 19 references indexed in Scilit:
- Report of Consensus Panel 2 from the 12th International Workshop on the management of Bing-Neel syndrome in patients with Waldenstrom’s MacroglobulinemiaSeminars in Hematology, 2025
- Outcomes of patients with relapsed/refractory lymphoplasmacytic lymphoma/waldenström macroglobulinemia treated with venetoclax: a multicenter retrospective analysisBlood Cancer Journal, 2025
- Zanubrutinib in Bing Neel syndrome: efficacy and tolerabilityLeukemia, 2025
- Zanubrutinib for the treatment of Bing–Neel syndromeBritish Journal of Haematology, 2025
- Bing–Neel syndrome, a rare manifestation of WM; a case report and review of literatureClinical Case Reports, 2024
- Evaluation and Management of Bing–Neel SyndromeHematology/Oncology Clinics of North America, 2023
- Bing-Neel Syndrome: Update on the Diagnosis and TreatmentClinical Lymphoma Myeloma and Leukemia, 2022
- Central nervous system involvement by Waldenström macroglobulinaemia (Bing‐Neel syndrome): a multi‐institutional retrospective studyBritish Journal of Haematology, 2015
- Leukoencephalopathy in Waldenstromʼs MacroglobulinemiaJournal of Neuropathology & Experimental Neurology, 1984
- Two Cases of Hyperglobulinaemia with Affection of the Central Nervous System on a Toxi‐Infectious Basis.1Acta Medica Scandinavica, 1936